Journal Mobile Options
Table of Contents
Vol. 223, No. 4, 2011
Issue release date: March 2012
Free Access
Dermatology 2011;223:311–315
(DOI:10.1159/000334805)

Eosinophilia during Psoriasis Treatment with TNF Antagonists

Malisiewicz B.a · Murer C.a · Pachlopnik Schmid J.b · French L.E.a · Schmid-Grendelmeier P.a · Navarini A.A.a
aDepartment of Dermatology and Allergology, University Hospital of Zurich, and bDivision of Immunology/Hematology/BMT, University Children’s Hospital Zurich, Zurich, Switzerland
email Corresponding Author


 Outline


 goto top of outline Key Words

  • Psoriasis vulgaris
  • Eosinophilia
  • Tumour necrosis factor α
  • Adalimumab
  • Etanercept

 goto top of outline Abstract

No abstract available

Copyright © 2010 S. Karger AG, Basel


 goto top of outline Author Contacts

Alexander A. Navarini
Department of Dermatology, University Hospital of Zurich
Gloriastrasse 31, CH–8091 Zurich (Switzerland)
Tel. +41 44 255 1111, E-Mail alexander.navarini@usz.ch


 goto top of outline Article Information

Published online: February 2, 2012
Number of Print Pages : 5


 goto top of outline Publication Details

Dermatology

Vol. 223, No. 4, Year 2011 (Cover Date: March 2012)

Journal Editor: Saurat J.-H. (Geneva)
ISSN: 1018-8665 (Print), eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

First-Page Preview
Abstract of Letter to Dermatology

 goto top of outline Author Contacts

Alexander A. Navarini
Department of Dermatology, University Hospital of Zurich
Gloriastrasse 31, CH–8091 Zurich (Switzerland)
Tel. +41 44 255 1111, E-Mail alexander.navarini@usz.ch


 goto top of outline Article Information

Published online: February 2, 2012
Number of Print Pages : 5


 goto top of outline Publication Details

Dermatology

Vol. 223, No. 4, Year 2011 (Cover Date: March 2012)

Journal Editor: Saurat J.-H. (Geneva)
ISSN: 1018-8665 (Print), eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.